What will be the medical insurance price of dasatinib in 2025?

Dasatinib (Dasatinib) is an important anti-tumor targeted drug, widely used in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This drug inhibits the kinase activity of BCR-ABL fusion protein and prevents the proliferation of cancer cells, and has shown significant efficacy in clinical treatment. The use of dasatinib is indicated for patients who have developed resistance to or relapsed from first-line treatment options such as imatinib. This makes it an important treatment option for these patients.

In China, dasatinib has obtained marketing approval and been included in the national medical insurance directory, aiming to reduce the financial burden on patients. According to the latest medical insurance policy, the reimbursement scope of dasatinib is usually limited to patients who meet specific conditions, including patients diagnosed with CML or ALL and confirmed by relevant tests to be BCR-ABL positive and other criteria. Such policy design enables more patients to obtain this effective treatment drug through medical insurance, ensuring that they can enjoy better medical services.

In terms of price, the common specifications of dasatinib in my country are50 mg 60 tablets and 20 mg 60 tablets, and their market price is about 10,000 yuan. Although this price is relatively high among anti-tumor drugs, it still attracts the attention of a large number of patients and doctors due to its excellent therapeutic effect. In the case of medical insurance reimbursement, the actual costs borne by patients will be significantly reduced, which will undoubtedly increase patients' accessibility to the drug.

However, it is worth noting that although the medical insurance coverage of dasatinib is gradually expanding, there are still some patients who are unable to obtain reimbursement due to their own conditions or medical insurance policy restrictions. Therefore, in clinical practice, doctors will develop individualized treatment plans based on the patient's specific conditions and discuss other financial burden solutions with the patient when necessary.

Reference materials:https://go.drugbank.com/drugs/DB01254